Stryker Corporation (NYSE:SYK) Price Target and Innovations Overview

• Jefferies sets a price target of $465 for Stryker Corporation (NYSE:SYK), indicating a potential upside of 21.76%.
• Stryker introduces new orthopedic products at the American Academy of Orthopedic Surgeons' 2026 Annual Meeting, including Triathlon knee implants.
• The company expands its Mako SmartRobotics platform and advances its power tools portfolio, reinforcing its commitment to innovation.

Stryker Corporation (NYSE:SYK) is a leading medical technology company known for its innovative orthopedic products. On March 4, 2026, Jefferies analyst Matthew Taylor set a price target of $465 for Stryker, suggesting a potential upside of 21.76% from its current trading price of $381.89. Jefferies maintains a Buy rating, indicating confidence in Stryker's growth prospects.

Stryker recently showcased its latest orthopedic innovations at the American Academy of Orthopedic Surgeons' 2026 Annual Meeting. The company introduced new Triathlon knee implants, including the Triathlon Gold and Medial Stabilized Insert, which enhance stability and address metal sensitivity. These advancements are part of Stryker's strategy to strengthen its position in the orthopedic market.

In addition to knee implants, Stryker expanded its Mako SmartRobotics platform and advanced its power tools portfolio. New offerings like the Mako Shoulder, RPS, and BPX and TPX HD tools aim to deepen Stryker's technology-driven orthopedics moat. These developments reflect Stryker's commitment to innovation and customer-driven enhancements.

Despite a recent dip in its stock price, Stryker's market capitalization remains robust at approximately $146.1 billion. The stock has fluctuated between a low of $380.87 and a high of $384.51 today, with a trading volume of 1,657,972 shares on the NYSE. Over the past year, SYK has reached a high of $404.87 and a low of $329.16, showcasing its resilience in the market.